Coherus BioSciences Valuation
| CHRS Stock | USD 1.03 0.08 8.42% |
Today, the firm appears to be overvalued. Coherus BioSciences shows a prevailing Real Value of $0.97 per share. The current price of the firm is $1.03. Our model approximates the value of Coherus BioSciences from analyzing the firm fundamentals such as Current Valuation of 249.07 M, return on equity of -16.57, and Profit Margin of 0.11 % as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Coherus BioSciences' price fluctuation is extremely dangerous at this time. Calculation of the real value of Coherus BioSciences is based on 3 months time horizon. Increasing Coherus BioSciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Coherus stock is determined by what a typical buyer is willing to pay for full or partial control of Coherus BioSciences. Since Coherus BioSciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Coherus Stock. However, Coherus BioSciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.03 | Real 0.97 | Hype 1.03 | Naive 1.04 |
The intrinsic value of Coherus BioSciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Coherus BioSciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Coherus BioSciences helps investors to forecast how Coherus stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Coherus BioSciences more accurately as focusing exclusively on Coherus BioSciences' fundamentals will not take into account other important factors: Coherus BioSciences Total Value Analysis
Coherus BioSciences is currently projected to have valuation of 249.07 M with market capitalization of 109.68 M, debt of 231.51 M, and cash on hands of 275.48 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Coherus BioSciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
249.07 M | 109.68 M | 231.51 M | 275.48 M |
Coherus BioSciences Investor Information
About 58.0% of the company shares are held by institutions such as insurance companies. The company last dividend was issued on the June 26, 1995. Coherus BioSciences had 2:1 split on the December 8, 1992. Based on the key indicators related to Coherus BioSciences' liquidity, profitability, solvency, and operating efficiency, Coherus BioSciences is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Coherus BioSciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Coherus BioSciences has an asset utilization ratio of 59.52 percent. This implies that the Company is making $0.6 for each dollar of assets. An increasing asset utilization means that Coherus BioSciences is more efficient with each dollar of assets it utilizes for everyday operations.Coherus BioSciences Ownership Allocation
Coherus BioSciences holds a total of 115.9 Million outstanding shares. Over half of Coherus BioSciences' outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Coherus BioSciences Profitability Analysis
The company reported the previous year's revenue of 266.96 M. Net Income was 28.51 M with profit before overhead, payroll, taxes, and interest of 149.41 M.About Coherus BioSciences Valuation
The stock valuation mechanism determines Coherus BioSciences' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Coherus BioSciences based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Coherus BioSciences. We calculate exposure to Coherus BioSciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Coherus BioSciences's related companies.Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. Coherus Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 368 people.
Coherus BioSciences Growth Indicators
Investing in growth stocks can be very risky. If the company such as Coherus BioSciences does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 114.8 M | |
| Quarterly Earnings Growth Y O Y | -0.755 | |
| Forward Price Earnings | 41.1523 |
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.